These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23898110)

  • 1. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
    Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma.
    Hong T; Zhang R; Cai D; Wu X; Hua D
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):285-91. PubMed ID: 22116317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
    Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    Sárosi V; Balikó Z
    Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
    Zhang RX; Cai DY; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
    Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R
    Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
    He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
    Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
    Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
    Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
    Shi SB; Hu RH; Qi JL; Tang XY; Tian J; Li R; Chang CX
    Med Oncol; 2013; 30(2):550. PubMed ID: 23576138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
    Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.
    Jiang X; Yang B; Lu J; Zhan Z; Li K; Ren X
    Tumour Biol; 2015 Feb; 36(2):861-9. PubMed ID: 25301443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.